- Home
- Browse
- National Institutes of Health
- RFA-HL-26-016
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
- Deadline
- 2026-10-21
- 48 days left
- Award ceiling
- $350,000
- Awards
- —
- Posted
- 2024-11-22
Summary
This Notice of Funding Opportunity (NOFO) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. […]
The rest of this announcement — free with an account
- →The full announcement text, not the first two sentences
- →All 3 review criteria reviewers score this against, extracted from this announcement
- →Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- →What similar funded projects received, from 219,000 past awards
No card required. Browsing and your first match are free.
More from National Institutes of Health
See all →NIH Director’s Transformative Research Award for Individual and Group Science (R01 Clinical Trial Optional)
The NIH Director's Transformative Research Award supports collaborative investigative teams or individual scientists who propose unusually bold and innovative research projects, which, if successful, would have a major impact in a broad area of relevance to the NIH.
3 review criteria on fileNIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileNIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileNIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileAlso in cardiovascular
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileAnimal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
Objective ORIP uses the P40 mechanism to support Animal and Biological Material Resource Centers in a variety of areas of biomedical science.
9 review criteria on fileNHLBI Program Project Applications (P01 Clinical Trials Optional)
The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders other programs including implementation science, health…
6 review criteria on fileOfficial announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-016.htmlSource: nih_guide+grants_gov. Always confirm dates with the funder.